α 2 Adrenoceptor: a Target for Neuropathic Pain Treatment
Neuropathic pain is originated from different alterations of the nervous system. The difficulty of treatment strongly impairs quality of life of affected people. It is associated with severe, chronic sensory disturbances characterized by spontaneous pain, increased responsiveness to painful stimuli and pain perceived in response to normally non-noxious stimuli. The underlying mechanisms are complex and involve both peripheral and central nervous components. The noradrenergic system plays a pivotal role in the control of pain since its widespread distribution in the "pain matrix" representing a valuable therapeutic target. This review focused on the α 2 adrenoceptor subtype modulation as strategy for neuropathic pain relief. Drugs acting as direct α 2 adrenoceptor agonists (clonidine and dexmedetomidine) were analyzed as well as the indirect α 2 adrenoceptor modulators. The overview included norepinephrine reuptake inhibitors (reboxetine, maprotiline), serotonin/norepinephrine reuptake inhibitors (venlafaxine, milnacipran, amitriptyline, duloxetine, bicifadine) and the compounds characterized by a double pharmacodynamic mechanism combining the norepinephrine reuptake inhibition and the ? opioid agonist profile (tramadol and tapentadol). A summary of recent compounds was illustrated..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Mini-reviews in ... medicinal chemistry - 17(2017), 2, Seite 95-107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lorenzo Di Cesare Mannelli [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC198976973X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC198976973X | ||
| 003 | DE-627 | ||
| 005 | 20230515183831.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170501 |
| 035 | |a (DE-627)OLC198976973X | ||
| 035 | |a (DE-599)GBVOLC198976973X | ||
| 035 | |a (PRQ)benthamscience_primary_http_www_eurekaselect_com_openurl_content_php_genre_article_issn_1389_5575_volume_17_issue_2_spage_950 | ||
| 035 | |a (KEY)04017706201700000170002000952adrenoceptoratargetforneuropathicpaintreatment | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 0 | |a Lorenzo Di Cesare Mannelli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a α 2 Adrenoceptor: a Target for Neuropathic Pain Treatment |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Neuropathic pain is originated from different alterations of the nervous system. The difficulty of treatment strongly impairs quality of life of affected people. It is associated with severe, chronic sensory disturbances characterized by spontaneous pain, increased responsiveness to painful stimuli and pain perceived in response to normally non-noxious stimuli. The underlying mechanisms are complex and involve both peripheral and central nervous components. The noradrenergic system plays a pivotal role in the control of pain since its widespread distribution in the "pain matrix" representing a valuable therapeutic target. This review focused on the α 2 adrenoceptor subtype modulation as strategy for neuropathic pain relief. Drugs acting as direct α 2 adrenoceptor agonists (clonidine and dexmedetomidine) were analyzed as well as the indirect α 2 adrenoceptor modulators. The overview included norepinephrine reuptake inhibitors (reboxetine, maprotiline), serotonin/norepinephrine reuptake inhibitors (venlafaxine, milnacipran, amitriptyline, duloxetine, bicifadine) and the compounds characterized by a double pharmacodynamic mechanism combining the norepinephrine reuptake inhibition and the ? opioid agonist profile (tramadol and tapentadol). A summary of recent compounds was illustrated. | ||
| 700 | 0 | |a Laura Micheli |4 oth | |
| 700 | 0 | |a Letizia Crocetti |4 oth | |
| 700 | 0 | |a Maria Paola Giovannoni |4 oth | |
| 700 | 0 | |a Claudia Vergelli |4 oth | |
| 700 | 0 | |a Carla Ghelardini |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Mini-reviews in ... medicinal chemistry |d Hilversum, the Netherlands [u.a.] : Bentham Science Publ., 2001 |g 17(2017), 2, Seite 95-107 |w (DE-627)363742387 |w (DE-600)2104081-3 |w (DE-576)435515101 |x 1389-5575 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:2 |g pages:95-107 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-5575&volume=17&issue=2&spage=95 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 2 |h 95-107 | ||